| Cash and cash equivalents |
127.94M |
| Restricted cash |
| Short-term investments |
| Trade accounts receivable, net |
48.58M |
| Prepaid expenses |
15.64M |
| Finished goods inventory held by the Company |
| Finished goods inventory held by others |
| Other current assets |
4.86M |
| Total current assets |
237.95M |
| Property and equipment, net of accumulated depreciation |
35.78M |
| Intangible assets, net of accumulated amortization |
749.42M |
| Non-current portion of deferred cost of license revenue |
2.43M |
| Other assets |
5.81M |
| Total assets |
1.32B |
| Accounts payable |
18.56M |
| Accrued expenses and other current liabilities |
89.37M |
| Deferred product revenue-Zanaflex tablets |
| Deferred product revenue-Zanaflex Capsules |
| Current portion of deferred license revenue |
9.06M |
| Current portion of revenue interest liability |
| Current portion of convertible notes payable |
1.13M |
| Total current liabilities |
118.12M |
| Non-current portion of deferred license revenue |
34.72M |
| Put/call liability |
| Non-current portion of revenue interest liability |
| Non-current portion of convertible notes payable |
0 |
| Common stock, $0.001 par value. Authorized 80,000,000 shares at June 30, 2011 and December 31, 2010; issued and outstanding 39,106,856 and 38,779,370 shares as of June 30, 2011 and December 31, 2010, respectively |
46K |
| Treasury stock at cost (12,420 shares at June 30, 2011 and December 31, 2010) |
-329K |
| Additional paid-in capital |
911.54M |
| Accumulated deficit |
-240.88M |
| Accumulated other comprehensive income |
-3.62M |
| Total stockholders' equity |
666.77M |
| Total liabilities and stockholders' equity |
1.32B |
